Accueil / Communiqués / SIRION Biotech Expands US Presence in Massachusetts

SIRION Biotech Expands US Presence in Massachusetts

Friday, February 1st 2019 at 3:01pm UTC

Europe’s Leading Commercial Provider of Viral Vector Technology Opens
Local Office in Cambridge

Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech
GmbH in Germany
(“SIRION”), offering the most comprehensive
portfolio of custom
viral vectors
for preclinical and clinical studies, today announced
the grand opening of a new office at 125 Cambridgepark Drive, Suite 301,
Cambridge, Massachusetts 02140. SIRION was pleased to meet its new
neighbors last night when it hosted a Bavarian-themed grand opening
event at the Forsyth
to meet and mingle with the Cambridge gene therapy scene.
World renowned gene cell therapy developers and viral vector experts
talked about the importance of the right viral vectors in making gene
therapy a reality. Gene therapy has seen strong clinical advancement,
and SIRION is becoming a partner of choice in this growing sector as
demonstrated by recent deals with Denali
, Orchard
, and an additional, undisclosed alliance with a major
public company that is advancing the discipline.

This press release features multimedia. View the full release here:

SIRION Biotech celebrated their move to Boston with a Grand Opening Reception at the Forsyth Institu ...

SIRION Biotech celebrated their move to Boston with a Grand Opening Reception at the Forsyth Institute in Cambridge. (Photo: Business Wire)

“As transduction and manufacturing efficiencies are critical issues in
gene therapy, SIRION’s viral vectors are essential to the success of
their partnering companies,” said Dieter Lingelbach, Chief Operating
Officer of SIRION Biotech. Dieter continued, “Since two-thirds of
SIRION’s revenue already comes from US customers and partners, opening
an office in a Life Science hub like Cambridge, Massachusetts further
demonstrates our commitment to supporting existing customers and further
expanding into the US market.”

About SIRION Biotech International Inc.

SIRION Biotech International is a wholly-owned subsidiary of SIRION
Biotech GmbH providing custom engineering and manufacturing services of
viral vectors for the life sciences industry. Its unique focus on
improving transduction efficiencies and safety make SIRION Biotech a
valuable technology partner for gene and cell therapy trials. LentiBOOSTTM
transduction reagent is actively used to improve, among others,
hematopoietic cell transductions in clinical trials. NextGen AAV capsid
evolution projects aim to improve tissue targeting and immune escape of
capsids to usher in a new generation of therapeutics for international
gene therapy companies.


Lisa DeScenza
Assistant Vice President, Integrated Communications

Source: SIRION Biotech International Inc.

Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …